Jump to main content
Jump to site search

Issue 8, 2017
Previous Article Next Article

Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents

Author affiliations

Abstract

The dynamic and crucial role of tubulin in different cellular functions rendered it a promising target in anticancer drug development. Combretastatin A-4 (CA-4), an inhibitor of tubulin polymerization isolated from natural sources, is a lead molecule with significant cytotoxicity against tumour cells. Owing to its non polar nature it exhibits low solubility in natural biological fluids, thereby prompting the development of new CA-4 based derivatives. The modification of this lead molecule was mostly carried out by keeping the crucial cis-orientation of the double bond intact, along with a trimethoxyphenyl aromatic ring, by employing different approaches. The issue of solubility was also addressed by the development of water soluble prodrugs of CA-4. The present review highlights the investigations into the parallel development of both new CA-4 based derivatives and prodrugs in the past few years.

Graphical abstract: Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents

Back to tab navigation

Publication details

The article was received on 03 May 2017, accepted on 03 Jul 2017 and first published on 04 Jul 2017


Article type: Review Article
DOI: 10.1039/C7MD00227K
Citation: Med. Chem. Commun., 2017,8, 1592-1603
  •   Request permissions

    Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents

    Z. S. Seddigi, M. S. Malik, A. P. Saraswati, S. A. Ahmed, A. O. Babalghith, H. A. Lamfon and A. Kamal, Med. Chem. Commun., 2017, 8, 1592
    DOI: 10.1039/C7MD00227K

Search articles by author

Spotlight

Advertisements